Bridging the gap: bitopic ligands of G-protein-coupled receptors

Research output: Contribution to journalArticleResearchpeer-review

Abstract

Although classical approaches to G-protein-coupled receptor (GPCR) drug design have targeted the orthosteric binding site, potentially all GPCRs possess druggable allosteric sites. In addition, it is clear that GPCRs can adopt multiple active states linked to distinct functional outcomes that can be stabilized by both allosteric and orthosteric ligands. Recent studies have begun to explore the possibilities of linking orthosteric and allosteric pharmacophores to yield bitopic ligands as an approach to achieve improved receptor affinity or selectivity. Furthermore, it is possible that previously identified functionally selective drugs may represent unappreciated bitopic ligands at this important class of drug targets. Here we discuss both the potential of bitopic ligands in GPCR drug discovery and the challenges associated with the design of such ligands.
Original languageEnglish
Pages (from-to)59 - 66
Number of pages8
JournalTrends in Pharmacological Sciences
Volume34
Issue number1
DOIs
Publication statusPublished - 2013

Cite this

@article{d8d98688dadf4f228e3303b685ac2c76,
title = "Bridging the gap: bitopic ligands of G-protein-coupled receptors",
abstract = "Although classical approaches to G-protein-coupled receptor (GPCR) drug design have targeted the orthosteric binding site, potentially all GPCRs possess druggable allosteric sites. In addition, it is clear that GPCRs can adopt multiple active states linked to distinct functional outcomes that can be stabilized by both allosteric and orthosteric ligands. Recent studies have begun to explore the possibilities of linking orthosteric and allosteric pharmacophores to yield bitopic ligands as an approach to achieve improved receptor affinity or selectivity. Furthermore, it is possible that previously identified functionally selective drugs may represent unappreciated bitopic ligands at this important class of drug targets. Here we discuss both the potential of bitopic ligands in GPCR drug discovery and the challenges associated with the design of such ligands.",
author = "Lane, {Jonathan Robert D} and Sexton, {Patrick Michael} and Arthur Christopoulos",
year = "2013",
doi = "10.1016/j.tips.2012.10.003",
language = "English",
volume = "34",
pages = "59 -- 66",
journal = "Trends in Pharmacological Sciences",
issn = "0165-6147",
publisher = "Elsevier",
number = "1",

}

Bridging the gap: bitopic ligands of G-protein-coupled receptors. / Lane, Jonathan Robert D; Sexton, Patrick Michael; Christopoulos, Arthur.

In: Trends in Pharmacological Sciences, Vol. 34, No. 1, 2013, p. 59 - 66.

Research output: Contribution to journalArticleResearchpeer-review

TY - JOUR

T1 - Bridging the gap: bitopic ligands of G-protein-coupled receptors

AU - Lane, Jonathan Robert D

AU - Sexton, Patrick Michael

AU - Christopoulos, Arthur

PY - 2013

Y1 - 2013

N2 - Although classical approaches to G-protein-coupled receptor (GPCR) drug design have targeted the orthosteric binding site, potentially all GPCRs possess druggable allosteric sites. In addition, it is clear that GPCRs can adopt multiple active states linked to distinct functional outcomes that can be stabilized by both allosteric and orthosteric ligands. Recent studies have begun to explore the possibilities of linking orthosteric and allosteric pharmacophores to yield bitopic ligands as an approach to achieve improved receptor affinity or selectivity. Furthermore, it is possible that previously identified functionally selective drugs may represent unappreciated bitopic ligands at this important class of drug targets. Here we discuss both the potential of bitopic ligands in GPCR drug discovery and the challenges associated with the design of such ligands.

AB - Although classical approaches to G-protein-coupled receptor (GPCR) drug design have targeted the orthosteric binding site, potentially all GPCRs possess druggable allosteric sites. In addition, it is clear that GPCRs can adopt multiple active states linked to distinct functional outcomes that can be stabilized by both allosteric and orthosteric ligands. Recent studies have begun to explore the possibilities of linking orthosteric and allosteric pharmacophores to yield bitopic ligands as an approach to achieve improved receptor affinity or selectivity. Furthermore, it is possible that previously identified functionally selective drugs may represent unappreciated bitopic ligands at this important class of drug targets. Here we discuss both the potential of bitopic ligands in GPCR drug discovery and the challenges associated with the design of such ligands.

UR - http://www.sciencedirect.com/science/article/pii/S0165614712001800

U2 - 10.1016/j.tips.2012.10.003

DO - 10.1016/j.tips.2012.10.003

M3 - Article

VL - 34

SP - 59

EP - 66

JO - Trends in Pharmacological Sciences

JF - Trends in Pharmacological Sciences

SN - 0165-6147

IS - 1

ER -